Table 4.
Distribution of antimicrobial resistance in Haemophilus influenzae and Haemophilus parainfluenzae isolates in healthy people and in patients with sarcoidosis
| No. (%) of resistant isolates | ||||||||
|---|---|---|---|---|---|---|---|---|
| Species | Place of isolation | Sxt | Te | Ctx | Caz | Sam | AmC | Am |
| Healthy people | ||||||||
| Haemophilus influenzae (n = 1) | Nasopharynx (n = 1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Haemophilus parainfluenzae (n = 65) | Nasopharynx (n = 65) | 8 (12.3) | 4 (6.2) | 4 (6.2) | 5 (7.7) | 3 (4.6) | 1 (1.5) | 10 (15.4) |
| Patients with sarcoidosis | ||||||||
| Haemophilus influenzae (n = 19) | Nasopharynx (n = 6) | 1 (16.7) | 0 | 0 | 0 | 0 | 1 (16.7) | 0 |
| Sputum (n = 13) | 1 (7.7) | 2 (15.4) | 0 | 0 | 0 | 0 | 0 | |
| Haemophilus parainfluenzae (n = 96) | Nasopharynx (n = 47) | 10 (21.3) | 9 (19.1) | 2 (4.3) | 3 (6.4) | 0 | 0 | 6 (12.8) |
| Sputum (n = 49) | 8 (16.3) | 6 (12.2) | 1 (2.0) | 5 (10.2) | 0 | 0 | 2 (4.1) | |
Abbreviations: Am ampicillin, AmC amoxycillin/clavulanate, Caz ceftazidime, Ctx cefotaxime, Sam ampicillin-sulbactam, Sxt trimethoprim/sulfametoxazole, Te tetracycline